-
Delaying Treatment ResistanceAdding a CDK 4/6 inhibitor extends progression-free survival for people with metastatic HR-positive, HER2-positive breast cancer.
by Thomas Celona
-
Rethinking the Role of RadiationChest radiation may not be necessary for people with intermediate-risk breast cancer.
by Thomas Celona
-
De-escalating Treatment for DCISResearch finds certain people with low-risk DCIS may be able to forgo surgery or radiation.
by Thomas Celona
Cancer Talk
Designing Clinical Trials for the Patient
Challenges in developing and studying treatments call for new ways of thinking about cancer research.
by Eric Fitzsimmons
Treating Smoldering Multiple MyelomaA monoclonal antibody drug reduced the risk of smoldering myeloma progressing to multiple myeloma in patients at high risk for disease progression.
by Sandra Gordon
Immunotherapy Improves Survival in Bladder CancerNew research indicates that adding immunotherapy to muscle-invasive bladder cancer treatment can improve event-free and overall survival.
by Laura Gesualdi-Gilmore
Cancer Patients Who Quit Smoking, Even Years After Diagnosis, Live LongerFindings from a recent study support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months of diagnosis.
by Kyle Bagenstose
From the AACR
-
AACR IO: Revolutionizing Treatment through ImmunotherapyThe AACR’s immuno-oncology meeting brings together the leading experts in immunotherapy to accelerate progress in cancer science and medicine.
-
A New Resource Provides a Sanctuary for Black TNBC PatientsThe Black TNBC Sanctuary was created to help Black women with triple-negative breast cancer get answers about their diagnosis and care.
Video
Dr. Humberto M. Guiot: Targeting Pancreatic Cancer in a Community-Based Clinical Trial
